Ekso Bionics (NASDAQ:EKSO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, ValuEngine raised Ekso Bionics from a “hold” rating to a “buy” rating in a report on Thursday, July 12th.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). The firm had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $3.03 million. Ekso Bionics had a negative net margin of 327.12% and a negative return on equity of 169.75%. On average, analysts forecast that Ekso Bionics will post -0.45 EPS for the current fiscal year.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
See Also: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.